Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

HER-family ligands promote acquired resistance to trastuzumab in gastric cancer.

Sampera A, Sánchez-Martín FJ, Arpí O, Visa L, Iglesias M, Menéndez S, Gaye É, Dalmases A, Clavé S, Gelabert-Baldrich M, Poulsen TT, Kragh M, Bellosillo B, Albanell J, Rovira A, Montagut C.

Mol Cancer Ther. 2019 Sep 4. pii: molcanther.0455.2019. doi: 10.1158/1535-7163.MCT-19-0455. [Epub ahead of print]

PMID:
31484705
2.

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.

Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.

3.

Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.

Nam HJ, Ching KA, Kan J, Kim HP, Han SW, Im SA, Kim TY, Christensen JG, Oh DY, Bang YJ.

Mol Cancer Ther. 2012 Feb;11(2):439-51. doi: 10.1158/1535-7163.MCT-11-0494. Epub 2011 Dec 1.

4.

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.

Arienti C, Zanoni M, Pignatta S, Del Rio A, Carloni S, Tebaldi M, Tedaldi G, Tesei A.

Oncotarget. 2016 Apr 5;7(14):18424-39. doi: 10.18632/oncotarget.7575.

5.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

6.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

7.

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

Leto SM, Sassi F, Catalano I, Torri V, Migliardi G, Zanella ER, Throsby M, Bertotti A, Trusolino L.

Clin Cancer Res. 2015 Dec 15;21(24):5519-31. doi: 10.1158/1078-0432.CCR-14-3066. Epub 2015 Aug 21.

8.

Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.

Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, Kodera Y, Nakanishi H.

Gastric Cancer. 2014;17(3):450-62. doi: 10.1007/s10120-013-0290-6. Epub 2013 Aug 15.

PMID:
23948998
9.

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.

Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.

Mol Cancer Ther. 2012 Sep;11(9):1978-87. doi: 10.1158/1535-7163.MCT-11-0730. Epub 2012 Jul 3.

10.

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL.

Clin Cancer Res. 2013 Oct 1;19(19):5390-401. doi: 10.1158/1078-0432.CCR-13-1038. Epub 2013 Aug 15.

11.

Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.

Jin MH, Nam AR, Park JE, Bang JH, Bang YJ, Oh DY.

Mol Cancer Ther. 2017 Jun;16(6):1145-1154. doi: 10.1158/1535-7163.MCT-16-0669. Epub 2017 Feb 21.

12.

An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.

Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi S, Aprile G, Simionato F, Boschi F, Zanotto M, Mina MM, Santoro R, Merz V, Sbarbati A, de Manzoni G, Scarpa A, Tortora G, Melisi D.

Clin Cancer Res. 2016 Dec 15;22(24):6164-6175. Epub 2016 Jun 7.

13.

Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance.

Liu W, Chang J, Liu M, Yuan J, Zhang J, Qin J, Xia X, Wang Y.

Oncotarget. 2017 Jul 11;8(28):45793-45806. doi: 10.18632/oncotarget.17415.

14.

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.

Keller S, Zwingenberger G, Ebert K, Hasenauer J, Wasmuth J, Maier D, Haffner I, Schierle K, Weirich G, Luber B.

Mol Oncol. 2018 Apr;12(4):441-462. doi: 10.1002/1878-0261.12170. Epub 2018 Mar 10.

15.

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity.

Jacobsen HJ, Poulsen TT, Dahlman A, Kjær I, Koefoed K, Sen JW, Weilguny D, Bjerregaard B, Andersen CR, Horak ID, Pedersen MW, Kragh M, Lantto J.

Clin Cancer Res. 2015 Sep 15;21(18):4110-22. doi: 10.1158/1078-0432.CCR-14-3312. Epub 2015 Apr 23.

16.

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.

Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R.

Breast Cancer Res. 2011 Aug 31;13(4):R84. doi: 10.1186/bcr2936.

17.

Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.

Poovassery JS, Kang JC, Kim D, Ober RJ, Ward ES.

Int J Cancer. 2015 Jul 15;137(2):267-77. doi: 10.1002/ijc.29378. Epub 2014 Dec 19.

18.

Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.

Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K.

Clin Cancer Res. 2011 Aug 1;17(15):5060-70. doi: 10.1158/1078-0432.CCR-10-2927. Epub 2011 Jun 23.

19.

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.

Park KS, Hong YS, Choi J, Yoon S, Kang J, Kim D, Lee KP, Im HS, Lee CH, Seo S, Kim SW, Lee DH, Park SR.

BMB Rep. 2018 Dec;51(12):660-665.

20.

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.

Zhu Y, Tian T, Zou J, Wang Q, Li Z, Li Y, Liu X, Dong B, Li N, Gao J, Shen L.

BMC Cancer. 2015 Nov 11;15:894. doi: 10.1186/s12885-015-1900-y.

Supplemental Content

Support Center